BridgeBio Oncology Therapeutics, Inc. Depreciation
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Depreciation of $100.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $100.00K, a 0.00% change year-over-year.
- BridgeBio Oncology Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $74.00K, a 37.04% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $84.00K, a 61.54% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $73.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $100.00K 10-Q · filed 2026-08-11 | $150.00K 10-Q · filed 2026-08-11 | $258.00K derived: sum of 3 quarters · filed 2026-08-11 | $331.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $74.00K 10-Q · filed 2026-05-12 | $158.00K derived: sum of 2 quarters · filed 2026-05-12 | $231.00K derived: sum of 3 quarters · filed 2026-05-12 | $331.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $84.00K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $157.00K derived: sum of 2 quarters · filed 2026-04-30 | $257.00K derived: sum of 3 quarters · filed 2026-08-11 | $280.00K POS AM · filed 2026-04-30 |
| 2025-09-30 | $73.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $173.00K derived: sum of 2 quarters · filed 2026-08-11 | $196.00K 10-Q · filed 2025-11-12 | $279.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-11 | $123.00K 10-Q · filed 2026-08-11 | $206.00K derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-03-31 | $54.00K 10-Q · filed 2026-05-12 | $106.00K derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $52.00K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $208.00K POS AM · filed 2026-04-30 | ||
| 2024-09-30 | $156.00K 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |